Povofortay®Receives European Approval as the First Once-Daily Oral Therapy for Moderate-to-Severe Hidradenitis Suppurativa in Adults

Incyte Receives European Commission Approval for Povofortay as a Once-Daily Oral Treatment for Moderate to Severe Hidradenitis Suppurativa

Incyte has announced that the European Commission (EC) has approved Povofortay® (povorcitinib) 45 mg and 75 mg for the treatment of eligible adults with moderate to severe hidradenitis suppurativa (HS). The approval introduces a new oral treatment option for patients living with this chronic and often debilitating inflammatory skin disease and represents an important milestone in the company’s efforts to expand its dermatology portfolio.

Povofortay is the first and only once-daily oral treatment approved in the European Union for eligible adults with moderate to severe HS, according to Incyte. The approval provides healthcare professionals with an additional treatment option for a condition that can significantly affect patients’ physical health, emotional well-being, daily activities, and overall quality of life.

The European Commission’s decision is based on positive results from the pivotal Phase 3 STOP-HS1 (NCT05620823) and STOP-HS2 (NCT05620836) clinical trials. Both studies evaluated the efficacy and safety of povorcitinib in patients with moderate to severe HS. The trials met their primary endpoints, demonstrating statistically significant improvements in clinical response at Week 12 compared with placebo at both evaluated doses.

Importantly, clinically meaningful responses were maintained through Week 54, with improvements observed across several measures of disease severity, skin pain, fatigue, and quality of life. The results also demonstrated consistent efficacy among patients previously treated with anti-tumor necrosis factor (anti-TNF) therapies, a population reflected in the European indication.

Bill Meury, Chief Executive Officer of Incyte, described the European Commission approval as an important milestone for the company and a significant development for people living with HS.

He said the approval advances a key growth driver for Incyte while providing patients and physicians with a new treatment option for a chronic disease that can be difficult to manage. Meury also emphasized that Povofortay’s once-daily oral administration offers physicians an important alternative when considering treatment approaches for eligible adults with moderate to severe HS.

Hidradenitis Suppurativa: A Chronic and Debilitating Inflammatory Skin Disease

Hidradenitis suppurativa is a chronic inflammatory skin condition characterized by recurring painful lumps, abscesses, nodules, and draining tunnels that commonly develop in areas where skin rubs together. These areas can include the armpits, groin, buttocks, and beneath the breasts.

The disease can be associated with persistent inflammation, recurring lesions, scarring, and drainage. Symptoms may fluctuate over time, with patients experiencing periods of worsening disease activity and ongoing discomfort. In more severe cases, repeated inflammatory episodes can lead to extensive skin damage and significantly interfere with everyday life.

Beyond its physical symptoms, HS can have a substantial impact on patients’ emotional and social well-being. Persistent pain, visible lesions, scarring, and drainage may affect mobility, sleep, personal relationships, and participation in routine activities. Patients may also experience fatigue and reduced confidence, contributing to a broader burden that extends beyond the skin.

Managing moderate to severe HS can be challenging because treatment needs to address several aspects of the disease. Reducing inflammatory lesions is important, but patients and healthcare professionals also seek improvements in pain, fatigue, and quality of life.

The European approval of Povofortay provides another treatment option for eligible adults, particularly in a disease area where achieving sustained disease control remains an important clinical objective.

Phase 3 STOP-HS1 and STOP-HS2 Trials Supported European Approval

The European Commission’s approval was supported by findings from the pivotal STOP-HS1 and STOP-HS2 Phase 3 clinical trials. Both studies were designed to evaluate the safety and efficacy of povorcitinib in adults with moderate to severe HS.

The trials investigated two doses of povorcitinib, 45 mg and 75 mg, and compared treatment outcomes with placebo. Their primary endpoint was the proportion of participants achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 12.

HiSCR50 is a clinical measure used to assess improvement in HS disease activity. It is defined as a reduction of at least 50% from baseline in the total number of abscesses and inflammatory nodules, without an increase in the number of abscesses or draining tunnels relative to baseline.

This endpoint provides a standardized way to measure changes in inflammatory disease activity. By assessing reductions in abscesses and inflammatory nodules while also accounting for the development of additional abscesses or draining tunnels, HiSCR50 helps evaluate whether patients are experiencing a meaningful clinical response.

Both STOP-HS1 and STOP-HS2 achieved their primary endpoints at Week 12. In the overall intent-to-treat (ITT) populations, both the 45 mg and 75 mg doses demonstrated improvements in HiSCR50 response rates compared with placebo.

The positive findings across both studies provided important evidence supporting the efficacy of povorcitinib in adults with moderate to severe HS.

Consistent Efficacy Observed in Patients Previously Treated with Anti-TNF Therapy

In addition to demonstrating efficacy in the overall study populations, the STOP-HS program showed consistent treatment responses among patients previously treated with anti-TNF therapies.

This patient population is particularly relevant because individuals who have received prior systemic treatment may continue to experience substantial disease activity and require additional therapeutic options.

The trials demonstrated that a greater proportion of patients in the post-anti-TNF population achieved HiSCR50 at Week 12 with povorcitinib compared with placebo.

The inclusion of this population in the European indication highlights the potential importance of povorcitinib for eligible adults whose disease remains challenging to manage following previous treatment.

The findings also support the broader clinical development strategy behind the candidate, which seeks to provide an oral treatment option for patients across relevant moderate to severe HS populations.

Durable Clinical Responses Maintained Through Week 54

Beyond the primary Week 12 assessment, the STOP-HS1 and STOP-HS2 studies evaluated treatment responses over an extended period. Results through Week 54 demonstrated clinically meaningful and durable responses across all groups in both trials.

According to Incyte, up to 71.4% of patients achieved HiSCR50 through Week 54.

The studies also assessed more stringent levels of clinical response to better understand the extent of improvement experienced by participants. These additional measures included HiSCR75 and HiSCR100.

HiSCR75 represents a reduction of at least 75% in the total abscess and inflammatory nodule count without an increase in abscess or draining tunnel count. HiSCR100 represents complete resolution of abscesses and inflammatory nodules according to the response criteria.

The results showed that up to 57% of participants achieved HiSCR75, while up to 29% achieved HiSCR100.

These findings indicate that clinically meaningful improvements were not limited to the primary response threshold. A proportion of participants experienced more substantial reductions in inflammatory lesions, demonstrating the potential for deeper clinical responses during treatment.

The durability of responses through Week 54 is also important in the context of HS, a chronic condition that often requires ongoing disease management. Sustained improvements may help patients and physicians evaluate treatment effectiveness over time rather than relying solely on short-term changes.

The company reported that improvements were observed across both evaluated doses and both pivotal studies.

Improvements in Skin Pain, Fatigue and Quality of Life

The impact of HS extends beyond the number of inflammatory lesions. Pain, fatigue, and disease-related limitations can significantly affect patients’ everyday experiences. For this reason, the STOP-HS program also evaluated patient-reported outcomes to assess changes in symptoms and quality of life.

At Week 54, a substantial proportion of participants across both povorcitinib doses reported clinically meaningful improvements in several patient-relevant measures.

Improvements in skin pain were reported in 40.5% to 46.8% of participants. Skin pain is an important component of HS disease burden because recurring painful lesions can interfere with movement, sleep, and daily activities.

The studies also showed clinically meaningful improvements in fatigue among 49.0% to 58.0% of participants. Fatigue can contribute to the broader physical and emotional burden of chronic inflammatory disease and may affect patients’ ability to maintain normal routines.

In addition, improvements were observed in skin condition-related quality of life, with 59.4% to 64.7% of participants experiencing clinically meaningful benefits. Improvements in HS-specific quality of life were reported in 33.7% to 40.2% of participants.

These findings suggest that the benefits observed during the trials extended beyond clinical measurements of inflammatory lesions. The improvements in pain, fatigue, and quality of life provide additional information about the potential effect of treatment on aspects of the disease that matter directly to patients.

For individuals living with moderate to severe HS, improvements in these areas may be particularly meaningful because the condition can affect personal comfort, confidence, social interactions, and the ability to participate in everyday activities.

Safety Profile Consistent Through 54 Weeks

In addition to evaluating clinical efficacy, the STOP-HS1 and STOP-HS2 trials assessed the safety and tolerability of povorcitinib over the treatment period.

According to Incyte, the overall safety profile of povorcitinib through 54 weeks was consistent with previously reported findings. Both the 45 mg and 75 mg doses were generally well tolerated, and no new or unexpected safety signals were identified.

The most frequently reported treatment-emergent adverse events (TEAEs) across both studies and doses included acne, nasopharyngitis, and upper respiratory tract infections.

Most of these reported events were classified as mild or moderate.

The safety findings are an important component of the clinical evidence supporting the European approval. Long-term treatment considerations are particularly relevant for chronic inflammatory diseases such as HS, where patients may require continued medical management.

The reported findings provide information about the tolerability of povorcitinib over an extended period, although healthcare professionals will continue to assess individual patient characteristics, treatment response, and potential risks when considering therapy.

Specialist Highlights the Broader Treatment Goals in HS

Professor Dr. Falk Bechara of Ruhr University Bochum, Germany, emphasized the challenges associated with managing HS and the importance of considering the full impact of the disease on patients.

He noted that many individuals living with HS experience a substantial burden that affects multiple aspects of their lives. According to Professor Bechara, treatment goals should extend beyond controlling disease activity and should also focus on improvements that patients can experience in their daily routines.

He explained that reducing inflammatory activity is only one part of effective disease management. Improvements in pain, fatigue, and quality of life are also important considerations when evaluating whether a treatment is meeting patients’ needs.

Professor Bechara said the European approval of Povofortay gives healthcare professionals and patients an important new option to consider when treating adults with moderate to severe HS.

He also highlighted the potential for the treatment to help address existing gaps in the management of this complex condition.

The specialist’s comments reflect the growing emphasis on patient-centered outcomes in inflammatory disease treatment. Clinical response measures remain essential, but understanding how treatment affects daily functioning and overall well-being is also important.

Once-Daily Oral Treatment Adds a New Option in Europe

According to Incyte, Povofortay is the first and only once-daily oral treatment approved in the European Union for eligible adults with moderate to severe HS.

The availability of an oral treatment option provides physicians with another approach when selecting therapies for patients with this chronic inflammatory disease.

The approval of both 45 mg and 75 mg strengths offers two approved dosing options within the European authorization. The clinical evidence supporting the decision includes results from both pivotal Phase 3 trials, with improvements observed at both evaluated doses.

The once-daily administration is also a key feature of the product’s positioning in the European market. It provides an oral alternative for eligible patients and expands the range of treatment choices available to physicians.

Incyte views the approval as an important commercial and strategic milestone, particularly as the company continues to develop its portfolio in dermatology and other therapeutic areas.

The company expects the new treatment option to contribute to its growth strategy while addressing an important medical need among people living with moderate to severe HS.

U.S. FDA Review Underway

Alongside the European regulatory milestone, Incyte is pursuing approval of povorcitinib in the United States.

The U.S. Food and Drug Administration (FDA) is currently reviewing the company’s New Drug Application (NDA) for povorcitinib as a treatment for moderate to severe HS.

The U.S. application is supported by results from the pivotal STOP-HS1 and STOP-HS2 clinical trials, which demonstrated improvements in HiSCR50 response rates at Week 12 and sustained clinical responses through Week 54.

Incyte anticipates a potential U.S. approval and commercial launch in the first quarter of 2027.

The ongoing FDA review represents another important regulatory milestone for the candidate. A U.S. decision could expand access to povorcitinib beyond Europe and provide an additional treatment option for eligible adults with moderate to severe HS.

However, the anticipated approval and launch remain subject to the FDA’s regulatory review and decision.

Advancing Treatment Options for Patients Living with HS

The European Commission’s approval of Povofortay marks a significant development in Incyte’s efforts to address the treatment needs of patients with moderate to severe hidradenitis suppurativa.

Supported by results from the STOP-HS1 and STOP-HS2 trials, povorcitinib demonstrated clinically meaningful responses at both evaluated doses, with improvements maintained through Week 54. The findings also included reductions in disease activity, higher levels of clinical response, and improvements in skin pain, fatigue, and quality of life.

The reported safety profile remained consistent over the 54-week assessment period, with no new or unexpected safety signals identified.

With European approval secured and U.S. regulatory review ongoing, Incyte is preparing for the next stage of povorcitinib’s development and potential commercialization.

The anticipated U.S. regulatory decision in the first quarter of 2027 could represent another important step in expanding access to the treatment.

For patients and healthcare professionals, the European authorization introduces a new once-daily oral option in a disease area where long-term management remains challenging. As Povofortay becomes available in the European market, its clinical performance and real-world use will be important in understanding its role in the evolving treatment landscape for moderate to severe HS.

About Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules, abscesses and draining tunnels that can lead to irreversible tissue destruction and scarring. Given the debilitating nature of the condition, it can have a profoundly negative effect on patients’ quality of life.2,4 Overactivity of the JAK/STAT signaling pathway is believed to drive inflammation involved in the pathogenesis and progression of HS.3 HS affects approximately 1% of the global population.4

About Povofortay® (povorcitinib)
Povofortay (povorcitinib) is an oral small-molecule JAK1 selective inhibitor approved in Europe as a treatment for active moderate to severe hidradenitis suppurativa (HS) in adults who have responded inadequately to, or who are intolerant or contraindicated to, an anti-tumor necrosis factor (TNF) therapy.

A New Drug Application (NDA) for povorcitinib in adults with moderate to severe HS is under review by the U.S. Food and Drug Administration.

Incyte has worldwide rights for the development and commercialization of Povofortay.

Povofortay is a registered trademark of Incyte.

For more information, see the Povofortay SmPC.

About Incyte®
Incyte is redefining what is possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation potential medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter